Enteric-coated cysteamine for the treatment of paediatric non-alcoholic fatty liver disease

Alimentary Pharmacology and Therapeutics

Volumn 33, Issue 9, 2011, Pages 1036-1044

  Dohil, R ^a   Schmeltzer, S ^a   Cabrera, B L ^a   Wang, T ^a   Durelle, J ^a   Duke, K B ^b   Schwimmer, J B ^a   Lavine, J E ^a,c  

^a RADY CHILDREN'S HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; MERCAPTAMINE;

ADOLESCENT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CHILD; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG COATING; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MALE; NONALCOHOLIC FATTY LIVER; OUTCOME ASSESSMENT; PATIENT MONITORING; PILOT STUDY; PRIORITY JOURNAL; SCHOOL CHILD;

ADIPONECTIN; ADOLESCENT; ANTIOXIDANTS; BODY MASS INDEX; BODY WEIGHT; CHILD; CYSTEAMINE; FATTY LIVER; FEMALE; HUMANS; INSULIN RESISTANCE; MALE; OXIDATIVE STRESS; PILOT PROJECTS; TABLETS, ENTERIC-COATED; TRANSAMINASES; TREATMENT OUTCOME;

EID: 79953723142     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2011.04626.x     Document Type: Article

References (36)

1. Schwimmer JB, Behling C, Newbury R, et al. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology 2005; 42: 641-9. (Pubitemid 41233657)
2. Barshop NJ, Sirlin CB, Schwimmer JB, Lavine JE,. Review article: epidemiology, pathogenesis and potential treatments of paediatric non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2008; 28: 13-24. (Pubitemid 351782810)
3. Sanyal AJ,. Mechanisms of disease: pathogenesis of nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol 2005; 2: 46-53. (Pubitemid 40812527)
4. Schwimmer JB, Deutsch R, Rauch JB, Behling C, Newbury R, Lavine JE,. Obesity, insulin resistance, and other clinicopathological correlates of pediatric nonalcoholic fatty liver disease. J Pediatr 2003; 143: 500-5. (Pubitemid 37352510)
5. Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120: 1183-92. (Pubitemid 32246672)
6. Wu G, Fang YZ, Yang S, Lupton JR, Turner ND,. Glutathione metabolism and its implications for health. J Nutr 2004; 134: 489-92. (Pubitemid 38298485)
7. Prescott LF, Stewart MJ, Proudfoot AT,. Cysteamine or N-acetylcysteine for paracetamol poisoning? Br Med J 1978; 1: 856-7. (Pubitemid 8317426)
8. Liu RM, Gaston Pravia KA,. Oxidative stress and glutathione in TGF-beta-mediated fibrogenesis. Free Radic Biol Med 2010; 48: 1-15.
9. Prescott LF, Critchley JA,. The treatment of acetaminophen poisoning. Annu Rev Pharmacol Toxicol 1983; 23: 87-101. (Pubitemid 13079368)
10. Clark JM,. Weight loss as a treatment for nonalcoholic fatty liver disease. J Clin Gastroenterol 2006; 40 (Suppl. 1): S39-43. (Pubitemid 44309542)
11. Lavine JE,. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr 2000; 136: 734-8. (Pubitemid 30415645)
12. Lesort M, Lee M, Tucholski J, Johnson GV,. Cystamine inhibits caspase activity. Implications for the treatment of polyglutamine disorders. J Biol Chem 2003; 278: 3825-30. (Pubitemid 36801110)
13. Kessler A, Biasibetti M, da Silva Melo DA, et al. Antioxidant effect of cysteamine in brain cortex of young rats. Neurochem Res 2008; 33: 737-44. (Pubitemid 351423138)
14. Kessler A, Biasibetti M, Feksa LR, et al. Effects of cysteamine on oxidative status in cerebral cortex of rats. Metab Brain Dis 2008; 23: 81-93.
15. Wood PL, Khan MA, Moskal JR,. Cellular thiol pools are responsible for sequestration of cytotoxic reactive aldehydes: central role of free cysteine and cysteamine. Brain Res 2007; 1158: 158-63. (Pubitemid 47068414)
16. Maher P, Lewerenz J, Lozano C, Torres JL,. A novel approach to enhancing cellular glutathione levels. J Neurochem 2008; 107: 690-700.
17. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-21. (Pubitemid 40770284)
18. Dohil R, Fidler M, Gangoiti JA, Kaskel F, Schneider JA, Barshop BA,. Twice-daily cysteamine bitartrate therapy for children with cystinosis. J Pediatr 2010; 156: 71-5, e1-3.
19. Dohil R, Gangoiti JA, Cabrera BL, Fidler M, Schneider JA, Barshop BA,. Long-term treatment of cystinosis in children with twice-daily cysteamine. J Pediatr 2010; 156: 823-7.
20. Dohil R, Newbury RO, Sellers ZM, Deutsch R, Schneider JA,. The evaluation and treatment of gastrointestinal disease in children with cystinosis receiving cysteamine. J Pediatr 2003; 143: 224-30. (Pubitemid 37082957)
21. Lumeng CN, Bodzin JL, Saltiel AR,. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 2007; 117: 175-84. (Pubitemid 46048464)
22. Kamada Y, Takehara T, Hayashi N,. Adipocytokines and liver disease. J Gastroenterol 2008; 43: 811-22.
23. Chitturi S, Abeygunasekera S, Farrell GC, et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35: 373-9. (Pubitemid 34106377)
24. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362: 1675-85.
25. Gahl WA, Bashan N, Tietze F, Bernardini I, Schulman JD,. Cystine transport is defective in isolated leukocyte lysosomes from patients with cystinosis. Science 1982; 217: 1263-5. (Pubitemid 12028677)
26. Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, McCullough AJ,. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 2009; 50: 1072-8.
27. Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002; 8: 1288-95. (Pubitemid 35373562)
28. Kamada Y, Nakamura T, Funahashi T, et al. Visceral obesity and hypoadiponectinemia are significant determinants of hepatic dysfunction: an epidemiologic study of 3827 Japanese subjects. J Clin Gastroenterol 2009; 43: 995-1000.
29. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79-83. (Pubitemid 29299050)
30. Yesilova Z, Yaman H, Oktenli C, et al. Systemic markers of lipid peroxidation and antioxidants in patients with nonalcoholic fatty liver disease. Am J Gastroenterol 2005; 100: 850-5. (Pubitemid 40592378)
31. Kataoka H, Imamura Y, Tanaka H, Makita M,. Determination of cysteamine and cystamine by gas chromatography with flame photometric detection. J Pharm Biomed Anal 1993; 11: 963-9. (Pubitemid 23340983)
32. Winterbourn CC, Hampton MB,. Thiol chemistry and specificity in redox signaling. Free Radic Biol Med 2008; 45: 549-61.
33. Brok J, Buckley N, Gluud C,. Interventions for paracetamol (acetaminophen) overdose. Cochrane Database Syst Rev 2006; 2: CD003328.
34. Mirza A, Liu SL, Frizell E, et al. A role for tissue transglutaminase in hepatic injury and fibrogenesis, and its regulation by NF-kappaB. Am J Physiol 1997; 272: G281-8.
35. Jeitner TM, Delikatny EJ, Ahlqvist J, Capper H, Cooper AJ,. Mechanism for the inhibition of transglutaminase 2 by cystamine. Biochem Pharmacol 2005; 69: 961-70. (Pubitemid 40312713)
36. Lorand L,. DRPLA aggregation and transglutaminase, revisited. Nat Genet 1998; 20: 231.